Bibliography

- Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., Herold, K. C., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Marks, J. B., Moore, W., Rodriguez, H., Russell, W. E., Schatz, D., … Ziegler, A.-G. (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine, 13(583). https://doi.org/10.1126/scitranslmed.abc8980
- Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., & Herold, K. C. (2023). Teplizumab and β-cell function in newly diagnosed type 1 diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2308743
- TZIELD. Prescribing Information. Provention Bio, Inc.